Many opportunistic pathogens live in surface-attached communities called biofilms that 16 generate ecological structure and can increase stress tolerance. Theory suggests that 17 bacterial populations evolving in biofilms may harbor greater genetic diversity and 18 become resistant to antibiotics by different pathways than in well-mixed environments. 19
Introduction
or planktonic conditions to ascertain whether these lifestyles select for differentpopulation size influences mutation availability and the response to selection (38, 39) . 113
The mutational dynamics of three lineages from each treatment were tracked by whole-114 population genomic sequencing ( Figure 1A ). We also sequenced 49 single clones isolated 115 from 22 populations at the end of the 12-day experiment to determine mutation linkage. 116
Evolution of CIP resistance 117
Passaging bacterial populations in the presence of antibiotics will select for fitter, more 118 resistant mutants if the populations do not go extinct. The rate and extent of evolved 119 resistance depends on the strength of antibiotic selection (12, 40), the distribution of 120 fitness effects of mutations that increase resistance to the drug (41), and the population 121 size of replicating bacteria (38, 39). The mode of bacterial growth may alter each of these 122 three variables, in theory generating different dynamics and magnitudes of AMR. In the 123 populations exposed to the increasing concentrations of CIP (the evolutionary rescue), 124 the magnitude of evolved CIP resistance differed substantially between planktonic and 125 biofilm populations. Planktonic populations became approximately 160x more resistant 126 concentrations of CIP ( Figure 1B ), but then the resistance of this population declined to 139 only 6x higher than the ancestral strain. This dynamic suggested that a mutant conferring 140 high-level resistance rose to intermediate frequency but was replaced by a more fit, yet 141 less resistant, mutant (this possibility is evaluated below). 142
Lower levels of resistance were observed in populations selected at subinhibitory 143 concentrations of CIP. Biofilm populations were 4x more resistant than the ancestor and 144 planktonic populations were 20x more resistant (Table S1 ). We can infer that biofilm 145 growth does not select for the high-level resistance seen in planktonic populations, instead 146 favoring mutants that would barely survive at their selected CIP concentration if not 147 grown in biofilms. It is important to note that these MIC measurements were made in 148 planktonic conditions according to the clinical standards (42) and that these values 149 increased greater than 100x when measured in biofilm (Table S2) . Our results correspond 150 with studies of clinical isolates in which those producing more biofilm (and likely having 151 other less fit mutations. Further, the stronger the selection for resistance, the greater theprobability of genetic parallelism -or the repeated evolution of the same gene, domain, 164 or even residue providing the best adaptation -among replicate populations (47) . Under 165 the conditions of these experiments, approximately 10 6 mutations occur in the first growth 166 cycle and roughly 10 7 mutations arise over the 12 days of selection, leading to a 167 probability of 0.98 that every site in the 4Mbp A. baumannii genome experiences a 168 mutation at least once over the course of the 12 day experiment (see Table S3 for details 169 of these calculations). The dramatic differences in the evolved resistance levels of 170 planktonic and biofilm populations suggested distinct genetic causes of resistance 171 resulting from different selective forces in these treatments. We also predicted to observe 172 greater genetic diversity in the biofilm treatments than in the planktonic cultures. Whereas 173 in well-mixed populations one or few genotypes outcompetes the other genotypes and 174 quickly achieves fixation (48), in structured environments like biofilms, multiple 175 beneficial mutations may arise to high frequency and persist, with potentially none fixing 176 owing to spatial structure and niche differentiation (13). 177
178
We conducted whole-population genomic sequencing of three replicates per treatment to 179 identify all contending mutations above a detection threshold of 5% (see Methods). The 180 spectrum of mutations from CIP-treated populations are consistent with expectations 181 from strong positive selection on altered or disrupted coding sequences (see Table 1 for  182   day-12 results and Table S4 for dynamics across the experiment). High nonsynonymous 183 to synonymous mutation ratios were observed in both lifestyles (8.5 in planktonic and 9.7 184 in biofilm). 43% of the total mutations in planktonic and 34% in biofilm were insertions 185 or deletions, which is vastly enriched over typical mutation rates of ~10 SNPs/indel under 186 neutral conditions (49, 50). Roughly 30% of the mutations in CIP-treated populations ofeither lifestyle occurred in intergenic regions (30% in planktonic-propagated populationsand 32% in biofilm ones). Of the intergenic mutations, 72% of the planktonic mutations 189 and 18% of the biofilm mutations occurred in promoters, 5' untranslated regions, or in 190 putative terminators (51). Consistent with theory, the spatial structure in biofilms generated more initial standing 201 diversity for selection to act upon. This higher standing diversity is important when 202 considering dosing and when antibiotic exposure may be low (e.g. in the external 203 environment or when bound to tissues) (52, 53) because biofilms with more allelic 204 diversity have a greater chance of survival to drug and immune attack (19) . 205
In contrast with the data observed in the populations evolving under CIP pressure, drug-206 free control populations contained no mutations that achieved high frequency during the 207 experiment ( Figures 2C and 2D ). These results suggest that the ancestral starting clone 208 was already well-adapted to our experimental conditions, perhaps because we had 209 previously propagated the A. baumannii ATCC 17978 clone under identical drug-free 210 conditions for 10 days. This preadaptation phase led to the fixation of mutations in threemodification of the direct antibiotic targets -gyrase A or B and topoisomerase IV -or 215 by the overexpression of efflux pumps reducing the intracellular concentrations of the 216 antibiotic (4). To directly associate genotypes with resistance phenotypes, we sequenced 217 49 clones isolated at the end of the experiment, the majority of which were selected to 218 delineate genotypes in the evolutionary rescue populations (Figures 2F and S2) . were made in both planktonic and biofilm conditions, demonstrating that even in thelifestyle selection environment they evolved in, the planktonic selected clones were less 288 fit as a result of antibiotic resistance trade-offs. However, one planktonic-evolved clone 289 with mutations in both gyrA and parC exhibited no significant fitness cost and high levels 290 of resistance. This suggests that, as in Pseudomonas aeruginosa, the parC mutation may 291 compensate for the cost imposed by gyrA mutation (67), an example of sign epistasis (68). 292
Overall, mutants selected in biofilm-evolved populations were less resistant than mutants 293 selected in planktonic populations ( Figure 1B 
Evolutionary interactions with other antibiotics 300
When a bacterium acquires resistance to one antibiotic, the mechanism of resistance can 301 also confer resistance to other antibiotics (cross-resistance) or increase the susceptibility 302 to other antibiotics (collateral sensitivity) (70). We tested the MIC of the evolved 303 populations to 23 different antibiotics. We observed changes in susceptibilities to 13 of 304 the 23 antibiotics tested, and these changes were growth mode dependent (Figure 4) . For 305 example, planktonic populations exhibited cross resistance to cefpodoxime and 306 ceftazidime but biofilm populations evolved collateral sensitivity to these cephalosporins. 307
Cross-resistance was associated genetically with adeN, adeS, gyrA or pgpB mutations, 308 and collateral sensitivity was associated with adeL mutations. Selection in these 309 environments evidently favors the activation of different efflux pumps or modified targets AdeIJK, regulated by adeS and adeN respectively, increased the resistance level to some 317 beta-lactams when overexpressed (77). However, production of AdeFGH, the efflux 318 pump regulated by adeL, decreased resistance to some beta-lactams and other families of 319 antibiotics or detergents by an unknown mechanism (74, 77). Even with the previously 320 demonstrated relationship between active proton pumps and the increase of sensitivity to 321 beta-lactams in P. aeruginosa (78), a clearer understanding of the physiological basis of 322 collateral sensitivity is important for using these features to control AMR evolution. (Table S7) We used experimental evolution of the opportunistic pathogen A. baumannii in both well-365 mixed and biofilm conditions to examine how lifestyle influences the dynamics, genetic 366 mechanisms, and direct and pleiotropic effects of resistance to a common antibiotic. 367
Experimental evolution is a powerful method of screening naturally arising genetic 368 variation for mutants that are the best fit in any condition (38, 93, 94). When population 369
sizes are large and reproductive rates are rapid, as they were here, the probability that all 370 possible single-step mutations that can increase both resistance and fitness occurred in 371 each population becomes nearly certain. The enrichment of the few mutations reported 372
here as well as their ordering with increasing CIP concentrations demonstrates that these 373 are the best such mutations in this A. baumannii strain and set of environmental 374 conditions, and the prevalence of some of these mutations in clinical samples illustrates 375 that they too may have been exposed to selection in biofilms. Likewise, the absence of 376 other mutations reported in shotgun mutant screens of resistance in A. baumannii (95) 377 means that these missing mutants engendered less resistance, fitness, or both. 378
Experimental evolution can be used in a wide variety of conditions, including in 379 susceptible hosts, to identify the most probable mutants that would be selected for under 380 antibiotic treatment and ultimately to enable forecasting of treatment outcomes, including 381 the diversification of the pathogen population and the likelihood of collateral sensitivity 382 or cross-resistance. Furthermore, knowledge of the prevailing lifestyle of the pathogen 383 population may be critically important for treatment design. Most infections are likelyantibiotics that promote biofilm as a primary response. For example, tobramycin is usedfor treating P. aeruginosa in cystic fibrosis patients (96) and promotes biofilm formation 387 (97, 98), wherein the evolution of antibiotic resistance without a detectable fitness cost 388 may arise during treatment. But the more diverse, biofilm-adapted lineages in our 389 experiments revealed a striking vulnerability to cephalosporins, which could provide a 390 new strategy for treatment. Broader still, conventional wisdom has long held that the 391 relationship between resistance and fitness is antagonistic, and that the efficacy of many 392 antimicrobials is aided by a severe fitness cost of resistance (27, 61, 69). This study 393
demonstrates that the form of the relationship between fitness and resistance can be 394 altered by the mode of growth, whereby biofilms can align resistance and fitness traits. 395
Therefore, a clearer picture of how the fitness landscape of various resistance pathways 396 depends on the environment, including both drug type and growth mode, and could be a 397 valuable forecasting tool in our armament to stem the rising AMR tide. We estimated the biofilm formation of the selected clones using a modification of the 458 previously described protocol (99). We resurrected each clone in 5 mL of M9 + containing 459 0.5 mg/L of CIP and grew them for 24 hours. For each strain, we transferred 50 µl intothe difference between the total populations (number of colonies/mL growing on thenonselective plates) and the resistant fraction (number of colonies/mL growing on the 487 plates containing CIP). As a control for calculating the correct ratio of susceptible vs. 488 resistant populations, we replica plated 50 to 100 colonies from the nonselective plates 489 onto plates containing CIP as previously described (101). Results are the average of three 490 to five independent experiments. 491
492

Genome sequencing 493
We sequenced whole populations of three evolving replicates per treatment. We 494 sequenced the populations at days 1, 3, 4, 6, 7, 9, 10, and 12 of the populations under 495 increasing concentrations of CIP (hereafter populations P1, P2, P3 and B1, B2, B3 for 496 planktonic and biofilm populations) and at days 1, 4, 9, and 12 of the populations under 497 subinhibitory concentration and no antibiotic treatments. In addition, we selected 49 498 clones for sequencing at the end of the experiment ( Figure 2F) . 12 of the clones were 499 recovered from the populations propagated in the absence of the antibiotic, 12 clones 500 from the subinhibitory concentrations of CIP treatment and 25 were isolated from the 501 increasing concentrations of antibiotic. We revived each population or clone from a 502 freezer stock in the growth conditions under which they were isolated (i.e. the same CIP 503 concentration which they were exposed to during the experiment) and grew for 24 hours. 504 DNA was extracted using the Qiagen DNAeasy Blood and Tissue kit (Qiagen, Hiden, 505 Germany). The sequencing library was prepared as described by Turner and colleagues 506 Figure S2  575 and Table S6 . G) The genetic organization of the RND efflux pumps is shown on the left. 576 MFP and OMP denote membrane fusion protein and outer membrane protein 577 respectively. All mutations found in the RND regulators are shown on the right. 578 
